{"id":"W3042190218","doi":"10.1016/j.ejca.2020.05.010","title":"Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma","year":2020,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hospital for Sick Children","funders":"Fondation contre le Cancer; Vlaamse regering; Kom op tegen Kanker; Fonds Wetenschappelijk Onderzoek; National Cancer Institute; Cancer Research UK; Neuroblastoma UK; Oak Foundation; Olivia Fund; Instituto de Salud Carlos III; Alex's Lemonade Stand Foundation for Childhood Cancer","keywords":"Neuroblastoma; Medicine; Clinical trial; Drug development; Drug; ATRX; Oncology; Pharmacology; Internal medicine; Biology; Mutation; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005399386,0.0007160865,0.001925569,0.0002959557,0.0002142896,0.00006563923,0.0007515871,0.00007441912,0.00005511311],"category_scores_gemma":[0.0001136494,0.0004452984,0.0005106124,0.0007485848,0.000261598,0.0002052832,0.0004208104,0.0009358946,0.000001246382],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003131804,"about_ca_system_score_gemma":0.005179662,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000009677792,"about_ca_topic_score_gemma":0.0001184607,"domain_scores_codex":[0.9957271,0.0004713622,0.00193565,0.000633125,0.0007225064,0.0005102576],"domain_scores_gemma":[0.9941679,0.0005941108,0.003192507,0.0002621336,0.001517902,0.000265495],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001326613,0.0003214612,0.0009505285,0.003027429,0.005060992,0.00006789657,0.001439847,0.00002554139,0.0003536804,0.000005677123,0.01301269,0.9744076],"study_design_scores_gemma":[0.006334264,0.002024049,0.01243862,0.005902158,0.0009029194,0.0001932429,0.0001647055,0.00002110319,0.00237362,0.000003782393,0.9692184,0.000423166],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.1356644,0.8544197,0.0002099166,0.002299285,0.0009606594,0.004630711,0.001470804,0.000037701,0.0003067919],"genre_scores_gemma":[0.01312421,0.9702139,0.01040731,0.001104083,0.001426859,0.0003495537,0.0001491929,0.0005181158,0.00270672],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9739845,"threshold_uncertainty_score":0.9997999,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04454238105661854,"score_gpt":0.3303695918244042,"score_spread":0.2858272107677856,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}